A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 After Administration of Multiple Ascending Doses.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2012
At a glance
- Drugs AZD 2820 (Primary)
- Indications Obesity
- Focus Adverse reactions
- 20 Jun 2012 Status changed from recruiting to discontinued.
- 19 Apr 2012 First patient has been dosed, according to a Palatin Technologies media release.
- 20 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.